<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734680</url>
  </required_header>
  <id_info>
    <org_study_id>LC2015L11</org_study_id>
    <nct_id>NCT02734680</nct_id>
  </id_info>
  <brief_title>IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer</brief_title>
  <acronym>IFCSLAPC</acronym>
  <official_title>Intraoperative Radiotherapy(IORT) Followed by Concurrent Chemoradiotherapy(CCRT) or Stereotactic Radiotherapy(SBRT) for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find the best model of combination of intraoperative&#xD;
      radiotherapy(IORT) and postoperative radiochemotherapy for pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is funded by Cancer Foundation of China. The trial is prepared to be registered on&#xD;
      the clinicaltrail.gov.&#xD;
&#xD;
      Quality assurance plan: every participant is enrolled or excluded by two practiced&#xD;
      investigators. And two investigators participated in all steps of the trail, including the&#xD;
      record of the data, and the investigators will compare the data. If the data is consistent,&#xD;
      the investigators would record the data; if not, the data would be checked and decided by the&#xD;
      two investigators. All the steps and data are site monitored and audited by the workers of&#xD;
      research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy&#xD;
      of Medical Sciences.&#xD;
&#xD;
      Data check: the investigators compare data entered into the registry against predefined rules&#xD;
      for range or consistency with other data fields in the registry.&#xD;
&#xD;
      Source data verification to assess the accuracy, completeness, or representativeness of&#xD;
      registry data by comparing the data to external data sources, including medical records and&#xD;
      electronic case report forms.&#xD;
&#xD;
      Data dictionary that contains detailed descriptions of each variable used by the registry,&#xD;
      including the source of the variable, coding information, and normal ranges if relevant.&#xD;
&#xD;
      Standard Operating Procedures to address registry operations and analysis activities, such as&#xD;
      participants recruitment, data collection, data management, data analysis, reporting for&#xD;
      adverse events, and change management. All registry operations would be done according to&#xD;
      specific steps, and by two practiced investigators.&#xD;
&#xD;
      Sample size assessment to specify the number of participants or participant years necessary&#xD;
      to demonstrate an effect. According to the formula to differ advantages and disadvantages,&#xD;
      the investigators need at least 70 participants to take part in the trail. The investigators&#xD;
      can recruit about 35 participants every year according to previous experiences, so the&#xD;
      investigators should recruit at least for two years.&#xD;
&#xD;
      Plan for missing data: the investigators would collect as much data as possible, and the&#xD;
      investigators exclude the participants who cannot cooperate on recruitment. And the&#xD;
      investigators manage situations according to statistical principles where variables are&#xD;
      reported as missing, unavailable, &quot;non-reported,&quot; uninterpretable, or considered missing&#xD;
      because of data inconsistency or out-of-range results.&#xD;
&#xD;
      Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of&#xD;
      survival time between the two groups, and the local control rate of the two groups would be&#xD;
      compared by chi square test. Statistical analyses would be performed by using IBM SPSS&#xD;
      Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P &lt; 0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overal survival</measure>
    <time_frame>2 years</time_frame>
    <description>OS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>2 years</time_frame>
    <description>DSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>2 years</time_frame>
    <description>LCR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy(CCRT) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Radiotherapy(SBRT) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemoradiotherapy(CCRT)</intervention_name>
    <description>Radiation and take gemcitabine(GEM)</description>
    <arm_group_label>Concurrent chemoradiotherapy(CCRT) Group</arm_group_label>
    <other_name>Concurrent chemoradiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiotherapy(SBRT)</intervention_name>
    <description>Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)</description>
    <arm_group_label>Stereotactic Radiotherapy(SBRT) Group</arm_group_label>
    <other_name>Stereotactic Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Taking S-1 orally after radiation</description>
    <arm_group_label>Concurrent chemoradiotherapy(CCRT) Group</arm_group_label>
    <arm_group_label>Stereotactic Radiotherapy(SBRT) Group</arm_group_label>
    <other_name>S-1 orally</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as locally advanced pancreatic cancer.&#xD;
&#xD;
          -  Cannot be treated by surgical resection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treated by chemotherapy or radiotherapy before.&#xD;
&#xD;
          -  With distant organ metastasis.&#xD;
&#xD;
          -  Cannot tolerate surgery (Intraoperative radiotherapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chengfeng Wang, B.A.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingtai Chen, PhD</last_name>
    <phone>+8618600258827</phone>
    <email>yingtai.chen@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuisheng Zhang, M.D.</last_name>
    <phone>+8618001302322</phone>
    <email>thelifeofwater@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingtai Chen, PhD</last_name>
      <phone>+8618600258827</phone>
      <email>yingtai.chen@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shuisheng Zhang, M.D</last_name>
      <phone>+18001302322</phone>
      <email>thelifeofwater@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chengfeng Wang, B.A.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>April 9, 2017</last_update_submitted>
  <last_update_submitted_qc>April 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Chengfeng Wang</investigator_full_name>
    <investigator_title>Director of Department of Abdominal Surgical Oncolgoy</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Intraoperative radiotherapy(IORT)</keyword>
  <keyword>Postoperative radiochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

